Literature DB >> 26711644

Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.

Lu Zhang1,2, Xiaoqiao Liu1, Xuegong Zhang3,4, Ronghua Chen5,6.   

Abstract

Hepatocellular carcinoma (HCC) is an aggressive and deadly cancer. The molecular pathogenesis of the disease remains poorly understood. To better understand HCC biology and explore potential biomarkers and therapeutic targets, we investigated the whole transcriptome of HCC. Considering the genetic heterogeneity of HCC, four datasets from four studies consisting of 15 pairs of HCC and adjacent normal samples were analyzed. We observed that the number of lncRNAs expressed in each HCC sample was consistently greater than the adjacent normal sample. Moreover, 15 lncRNAs were identified expressed in five to seven HCC tissues but were not detected in any adjacent normal tissue. Differential expression analysis detected 35 up- and 80 down-regulated lncRNAs in HCC samples compared with adjacent normal samples. In addition, five differentially expressed lncRNAs were predicted to play a role in oxidation and reduction process. With regard to splicing alterations, we identified nine highly recurrent differential splicing events belonging to eight genes USO1, RPS24, CCDC50, THNSL2, NUMB, FN1 (two events), SLC39A14 and NR1I3. Of them, splicing alterations of SLC39A14 and NR1I3 were reported for the association with HCC for the first time. The splicing dysregulation in HCC may be influenced by three splicing factors ESRP2, CELF2 and SRSF5 which were significantly down-regulated in HCC samples. This study revealed uncharacterized aspects of HCC transcriptome and identified important lncRNAs and splicing isoforms with the potential to serve as biomarkers and therapeutic targets for the disease.

Entities:  

Keywords:  Alternative splicing; HCC; Long noncoding RNA (lncRNA); RNA-Seq

Mesh:

Substances:

Year:  2015        PMID: 26711644     DOI: 10.1007/s00438-015-1163-y

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  113 in total

1.  Comparative transcriptome analysis reveals that the extracellular matrix receptor interaction contributes to the venous metastases of hepatocellular carcinoma.

Authors:  Hong Zhang; Junyi Ye; Xiaoling Weng; Fatao Liu; Lin He; Daizhan Zhou; Yun Liu
Journal:  Cancer Genet       Date:  2015-06-18

2.  The Golgi protein p115 associates with gamma-tubulin and plays a role in Golgi structure and mitosis progression.

Authors:  Andreea E Radulescu; Shaeri Mukherjee; Dennis Shields
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

3.  Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Ming-chun Lai; Zhe Yang; Lin Zhou; Qian-qian Zhu; Hai-yang Xie; Feng Zhang; Li-ming Wu; Lei-ming Chen; Shu-sen Zheng
Journal:  Med Oncol       Date:  2011-06-16       Impact factor: 3.064

Review 4.  Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.

Authors:  Carmen Berasain; Saioa Goñi; Josefa Castillo; María Ujue Latasa; Jesús Prieto; Matías A Avila
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

5.  Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.

Authors:  Katrin Panzitt; Marisa M O Tschernatsch; Christian Guelly; Tarek Moustafa; Martin Stradner; Heimo M Strohmaier; Charles R Buck; Helmut Denk; Renée Schroeder; Michael Trauner; Kurt Zatloukal
Journal:  Gastroenterology       Date:  2006-08-14       Impact factor: 22.682

6.  Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.

Authors:  Anna Corrionero; Belén Miñana; Juan Valcárcel
Journal:  Genes Dev       Date:  2011-03-01       Impact factor: 11.361

7.  Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.

Authors:  Yinying Lu; Wanping Xu; Junfang Ji; Dechun Feng; Carole Sourbier; Youfeng Yang; Jianhui Qu; Zhen Zeng; Chunping Wang; Xiujuan Chang; Yan Chen; Alok Mishra; Max Xu; Min-Jung Lee; Sunmin Lee; Jane Trepel; W Marston Linehan; Xinwei Wang; Yongping Yang; Len Neckers
Journal:  Hepatology       Date:  2015-07-03       Impact factor: 17.425

Review 8.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

9.  Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Authors:  Yoshihiko Kotake; Koji Sagane; Takashi Owa; Yuko Mimori-Kiyosue; Hajime Shimizu; Mai Uesugi; Yasushi Ishihama; Masao Iwata; Yoshiharu Mizui
Journal:  Nat Chem Biol       Date:  2007-07-22       Impact factor: 15.040

10.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

View more
  17 in total

Review 1.  Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability.

Authors:  Maddalen Jimenez; María Arechederra; Matías A Ávila; Carmen Berasain
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-31

2.  Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.

Authors:  Rolando A R Villacis; Tatiane R Basso; Luisa M Canto; Maísa Pinheiro; Karina M Santiago; Juliana Giacomazzi; Cláudia A A de Paula; Dirce M Carraro; Patrícia Ashton-Prolla; Maria I Achatz; Silvia R Rogatto
Journal:  J Mol Med (Berl)       Date:  2017-01-16       Impact factor: 4.599

Review 3.  The Multiple Faces of the Metal Transporter ZIP14 (SLC39A14).

Authors:  Tolunay B Aydemir; Robert J Cousins
Journal:  J Nutr       Date:  2018-02-01       Impact factor: 4.798

4.  An alternative splicing signature model for predicting hepatocellular carcinoma-specific survival.

Authors:  Sheng Dong; Li-Jun Lu
Journal:  J Gastrointest Oncol       Date:  2020-10

5.  Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors.

Authors:  Olga Y Burenina; Natalia L Lazarevich; Inna F Kustova; Daria A Shavochkina; Ekaterina A Moroz; Nikolay E Kudashkin; Yuriy I Patyutko; Alexey V Metelin; Eduard F Kim; Dmitry A Skvortsov; Timofei S Zatsepin; Maria P Rubtsova; Olga A Dontsova
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-12       Impact factor: 4.553

Review 6.  Recent Advances in the Role of SLC39A/ZIP Zinc Transporters In Vivo.

Authors:  Teruhisa Takagishi; Takafumi Hara; Toshiyuki Fukada
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

7.  A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma.

Authors:  Kuan-Ting Lin; Wai Kit Ma; Juergen Scharner; Yun-Ru Liu; Adrian R Krainer
Journal:  Genome Res       Date:  2018-02-15       Impact factor: 9.043

8.  TRPV4-dependent induction of a novel mammalian cold-inducible protein SRSF5 as well as CIRP and RBM3.

Authors:  Takanori Fujita; Hiroaki Higashitsuji; Hisako Higashitsuji; Yu Liu; Katsuhiko Itoh; Toshiharu Sakurai; Takahiro Kojima; Shuya Kandori; Hiroyuki Nishiyama; Motoi Fukumoto; Manabu Fukumoto; Koji Shibasaki; Jun Fujita
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

9.  The More the Merrier-Complexity in Long Non-Coding RNA Loci.

Authors:  Christian Ziegler; Markus Kretz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

10.  Comprehensive Network Analysis Reveals Alternative Splicing-Related lncRNAs in Hepatocellular Carcinoma.

Authors:  Junqing Wang; Xiuquan Wang; Akshay Bhat; Yixin Chen; Keli Xu; Yin-Yuan Mo; Song Stephen Yi; Yunyun Zhou
Journal:  Front Genet       Date:  2020-07-15       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.